Topics
Low-grade gliomas | Treatment | Targeted therapy | Safusidenib
Home > Publications > Topics > Low-grade gliomas > Treatment > Targeted terapy > Safusidenib
Drummond KJ, Spiteri M, Cain SA, Jones J, Shaya S, Topp M, Lu T,
Tobler R, Valkovic AL, Moore Z, Fatunla OE, Kriel J, Moffet JJD,
McAlpine H, Rosier M, Guan H, Dimou J, Schadewaldt V,
Roberts-Thomson S, McArdle D, Lui E, Voelker-Albert M, di Sanzo S,
Nijagal B, Narayana VK, Mitchell CB, Vissers JHA, Grimmond S,
Rosenthal MA, Palmer LM, Best SA, Freytag S, Whittle
JR.
Perioperative IDH
inhibition in treatment-naive
IDH-mutant glioma: a pilot trial.
Nat
Med. 2025 Aug 21. doi:
10.1038/s41591-025-03884-4. PMID:
40841487. Interventional study. ˍ
NCT05577416;
AI
Overview.
Arakawa Y, Saito R, Kanemura Y, Mishima K, Koriyama S, Narita Y,
Kumabe T, Motomura K, Sugiyama K, Yamasaki F, Mukasa A, Kanamori
M, Kuga D, Nagane M, Kakurai Y, Isobe K, Nakamura H.
Phase
II study of safusidenib erbumine in patients with chemotherapy-
and radiotherapy-naïve isocitrate dehydrogenase 1-mutated WHO
grade 2 gliomas.
Neuro
Oncol. 2025 Nov 8:noaf258. doi:
10.1093/neuonc/noaf258. PMID:
41206766. Interventional
study.
ˍ